The goal of the Tissue Core is to provide investigators in the Pancreas SPORE with high quality patient data,DNA, RNA, serum, circulating tumor cells, and pancreas tissues from pancreatic cancer patients, and tomake these resources available for future studies. The activities of the Tissue Core will be overseen underthe combined leadership of Dr. W. Lingle, Director of the TACMA and Co-Director of the BAP SharedResources of the Mayo Clinic Cancer Center, and Dr. T. Smyrk, anatomic pathologist. The activities of theTissue Core will be conducted in a way that does not compromise patient confidentiality, yet will be ascomprehensive as possible in the materials that are provided. The acquisition of human tissue andsubsequent cellular/molecular analysis of that tissue within the context of pathology and patient data are keyto many laboratory-based studies of cancer. The Mayo Clinic has a strong tradition of ethically sound supportof research that links tissue acquisition and patient data records. Paraffin embedded tissues, histologicalslides, and associated patient charts from surgeries performed since the first decade of the 1900's aremaintained in Mayo's Tissue Registry and the Mayo Archives. The Tissue and Cell Molecular Analysis(TACMA) Shared Resource of the Mayo Clinic Cancer Center is a resource of expertise and service forimmunohistochemistry, laser capture microdissection, tissue microarray preparation, and digital imaging.Likewise, the Biospecimen Accessioning and Processing (BAP) Shared Resource of the Mayo Clinic CancerCenter is the primary site of accessioning and standardized processing of blood, frozen tissue, and othernon-paraffin embedded specimens collected explicitly for research. New methodologies for biospecimencollection, processing, and analysis will be developed in the Tissue Core. These methodologies will beshared with other Mayo SPORE Tissue Cores and integrated with services offered by the BAP and TACMAShared Resources. Tissue Core activities will be closely coordinated with the newly formed ClinicalResearch Core and with the Biostatistics Core to provide seamless linkage of clinical annotations withresearch biospecimens. Core D will be integrated with the existing tissue-oriented Cancer Center sharedresources and the other scientific Cores in this SPORE in order to provide a coordinated, centralized,dedicated program for standardized collection, accessioning, processing, and evaluation of biospecimensand patient data from pancreatic cancer patients. Furthermore, the Tissue Core will make biospecimenscollected for this SPORE available to the pancreas cancer research community in order to stimulatetranslational research with the goal of improving prevention and treatment of pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA102701-06
Application #
7510940
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-08-31
Support Year
6
Fiscal Year
2008
Total Cost
$141,933
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wolf, Susan M; Scholtes, Emily; Koenig, Barbara A et al. (2018) Pragmatic Tools for Sharing Genomic Research Results with the Relatives of Living and Deceased Research Participants. J Law Med Ethics 46:87-109
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Chaffee, Kari G; Oberg, Ann L; McWilliams, Robert R et al. (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 20:119-127
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Zhang, Mingfeng; Lykke-Andersen, Soren; Zhu, Bin et al. (2018) Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut 67:521-533
Kanamori, Karina S; de Oliveira, Guilherme C; Auxiliadora-Martins, Maria et al. (2018) Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Bio Protoc 8:
Hu, Chunling; Hart, Steven N; Polley, Eric C et al. (2018) Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA 319:2401-2409

Showing the most recent 10 out of 336 publications